Receptor Tyrosine Kinase Treatment Market Size & Share, by Product Type (Epidermal Growth Factor Receptor [EGFR] Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor [VEGFR] Tyrosine Kinase Inhibitors); Application (Lung Cancer, Breast Cancer, Renal Cell Cancer); Distribution (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3626
  • Published Date: Feb 16, 2023
  • Report Format: PDF, PPT

Companies Dominating the Receptor Tyrosine Kinase Treatment Landscape

    • Bristol-Myers Squibb Company
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Boehringer Ingelheim GmbH
    • Eton Bioscience, Inc.
    • GlaxoSmithKline plc
    • Merck KGaA
    • AstraZeneca
    • Novartis AG
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • A study conducted provided information on the potential cardiotoxicity of a list of FDA approved Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors and ranked them by their potential cardiotoxic risk associated in patients with solid tumors.

  • A research investigated the efficacy of EGFR-TKIs in older patients, where patients of 65 years or older with EGFR-mutated Stage IIIB–IV non-small-cell lung cancer (NSCLC) were enrolled and the efficacy and prognosis of first-line EGFR-TKI treatment was evaluated. EGFR-TKIs are standard first-line treatments for advanced EGFR-mutated non-small-cell lung cancer (NSCLC) patients.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3626
  • Published Date: Feb 16, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are surge in prevalence of obesity, growing investment in healthcare, clinical approval of kinase inhibitors, and others.

The market is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2023-2035.

High cost of tyrosine kinase therapies, lack of funds for R&D activities, and challenges faced by clinical trials for commercialization of tyrosine kinase inhibitors are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Eton Bioscience, Inc., GlaxoSmithKline plc, and more.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, application, distribution channel and by region.

The breast cancer segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying